Y-MABS THERAPEUTICS INC. - COMMON STOCK
8.1500
24-12月-24 13:45:00
15 分の遅延
株式
+0.0400
+0.49%
本日の幅
7.8000 - 8.2250
ISIN
N/A
ソース
NASDAQ
-
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
14 3 2024 09:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
04 3 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
29 2 2024 16:05:00 提供 Nasdaq GlobeNewswire
-
16 2 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 1 2024 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
13 12 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
13 11 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
31 10 2023 07:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
18 10 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
17 10 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces Publication in Cancers
16 10 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
21 9 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences in September
06 9 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
10 8 2023 16:05:02 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences
02 8 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
01 8 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 5 2023 09:00:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 5 2023 09:00:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 5 2023 09:00:00 提供 Nasdaq GlobeNewswire
-
08 5 2023 16:01:00 提供 Nasdaq GlobeNewswire